BDNF

Boost in Nerve-Growth Protein Helps Explain Why Running Supports Brain Health

Retrieved on: 
Monday, May 16, 2022
Department, NYU Langone Health, Parkinson's disease, Motor neuron, Running, Journal, Doctor of Philosophy, Exercise, National Institute, Memory, Patient, Frasier, Motivation, Movement disorders, Learning, NYU, BDNF, Physiology, Dopamine, Depression, Research, Mouse, Brain, Brain-derived neurotrophic factor, Marlene, Female, National Institute on Drug Abuse, The Journal of Neuroscience, Rest, Human, Movement, New York University Grossman School of Medicine, Male, Lists of diseases, Beer, Management, Pharmaceutical industry, Neuroscience, Catia Bastioli, Neurosurgery

Experts have long understood that regular running raises dopamine activity in the brain and may protect nerve cells from damage.

Key Points: 
  • Experts have long understood that regular running raises dopamine activity in the brain and may protect nerve cells from damage.
  • In addition, past research has tied exercise-driven boosts in the dopamine-triggering chemical called brain-derived neurotrophic factor (BDNF) and in dopamine levels to improvements in learning and memory.
  • Additionally, when BDNF levels were artificially reduced, running did not lead to additional dopamine release.
  • Further funding support was provided by the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders.

Sensorineural Hearing Loss Market Pipeline Research Report 2022: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, NDA, News, Clinical trial, Sensorineural hearing loss, Audion, Cochlea, II, Hearing loss, Hearing, Technology, Discovery, BDNF, Brain-derived neurotrophic factor, Safety, Acquisition, Therapy, Pharmaceutical industry, Notch

The "Sensorineural Hearing Loss - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Sensorineural Hearing Loss pipeline landscape.

Key Points: 
  • The "Sensorineural Hearing Loss - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Sensorineural Hearing Loss pipeline landscape.
  • The assessment part of the report embraces, in depth Sensorineural Hearing Loss commercial assessment and clinical assessment of the pipeline products under development.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Sensorineural Hearing Loss R&D.
  • The companies which have their Sensorineural Hearing Loss drug candidates in the most advanced stage, i.e.

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

Retrieved on: 
Wednesday, April 20, 2022
CEO, Population, U.S. Securities and Exchange Commission, Pathology, Hearing, Tinnitus, PGIC, Security (finance), Research, Synapse, Huber loss, Annual report, Electricity, Computer, Compliance, Private Securities Litigation Reform Act, AE, GLOBE, Department, Risk, Patient, Cochlea, Noise-induced hearing loss, Social isolation, Growth, Review, Hearing loss, Technology, Dementia, Depression, Webcast, SEC, Forward-looking statement, Carnegie Mellon University, SIN, University, Speech, BDNF, Brain-derived neurotrophic factor, Safety, Assistant professor, Hearing aid, FDA, Otorhinolaryngology, Biomedical engineering, Neurotology, Therapy, Communes of Burundi, Ear, Silviculture, Pharmaceutical industry, Dentistry, Fine chemical, Psychology

ET

Key Points: 
  • ET
    SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
  • The design of the Phase 2a trial was the same as the previous Phase 1/2 trial.
  • Most of the patients enrolled in this trial also had moderate-to-severe high-frequency hearing loss measured with standard audiometric testing.
  • Based on these positive results, Otonomy intends to initiate a full dose-ranging Phase 2 trial in hearing loss patients by the end of 2022.

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics

Retrieved on: 
Wednesday, March 2, 2022
Ophthalmology, Patient, CDTI, Science, Neuroscience, Severe cognitive impairment, Optic nerve, Quality of life, Neurodegeneration, Retinal, Safety, Spinal cord, PK, Health, Particle-size distribution, University, Glaucoma, Program, Therapy, Parkinson's disease, Public university, APHP, IOP, Board, Geographic atrophy, Experimental autoimmune encephalomyelitis, AON, Company, Epilepsy, Disease, CNS, Inflammation, Technology, Autonomous University of Barcelona, CEO, Optic neuropathy, Retina, Industrialisation, Optic neuritis, Multiple sclerosis, Center, Partnership, Brain, Immune system, Agreement, Achievement, Paralysis, BDNF, La, Medical imaging, Pharmaceutical industry, EU, Pecten oculi

In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures.

Key Points: 
  • In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures.
  • Oculis is currently planning the expansion of the program in ophthalmology working with the regulatory agencies in the US, EU and China amongst others.
  • Glaucoma is a leading global cause of irreversible blindness, and despite IOP lowering treatments, a significant proportion of patients still go blind.
  • With OCS-05, we have the potential to bring to market the first neuroprotective for glaucoma and other optic neuropathies."

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics

Retrieved on: 
Wednesday, March 2, 2022
Ophthalmology, Patient, CDTI, Science, Neuroscience, Severe cognitive impairment, Optic nerve, Quality of life, Neurodegeneration, Safety, Spinal cord, PK, Health, Particle-size distribution, La, University, Glaucoma, Public university, Therapy, APHP, IOP, Geographic atrophy, Experimental autoimmune encephalomyelitis, Epilepsy, AON, Disease, CNS, Inflammation, University of Barcelona, Technology, CEO, Optic neuropathy, Retina, Industrialisation, Optic neuritis, Multiple sclerosis, Center, Partnership, Brain, Agreement, Achievement, Paralysis, BDNF, Medical imaging, Pharmaceutical industry, EU, Pecten oculi

In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures.

Key Points: 
  • In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures.
  • Oculis is currently planning theexpansion of theprogram in ophthalmology working with theregulatoryagencies in the US, EU and China amongst others.
  • Glaucoma is a leading global cause of irreversible blindness, and despite IOP lowering treatments, a significant proportion of patients still go blind.
  • With OCS-05, we have the potential to bring to market the first neuroprotective for glaucoma and other optic neuropathies.

Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®

Retrieved on: 
Tuesday, February 15, 2022
Amyotrophic lateral sclerosis, NASDAQ, EMA, Orphan drug, Food, European Medicines Agency, Company, California Institute for Regenerative Medicine, Neurodegeneration, California Institute for Quantitative Biosciences, Phrase, NGF, MS, Annual report, IP, Adult, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Cell, NTFS, CIRM, National, FDA, Regenerative medicine, BDNF, Patent, HGF, Research, Hepatocyte growth factor, VEGF, GDNF, Multiple sclerosis, Microsoft, Nerve growth factor, Vaccine, Pharmaceutical industry, Brainstorm, ALS, EU

"We are committed to the development of NurOwn as a potential treatment for ALS and other neurodegenerative diseases.

Key Points: 
  • "We are committed to the development of NurOwn as a potential treatment for ALS and other neurodegenerative diseases.
  • This patent, which covers the industrial manufacturing process for NurOwn developed by Brainstorm's scientists, enhances our ability to do so worldwide," said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics.
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • Brainstorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Prilenia Announces Completion of Patient Enrollment Ahead of Schedule in the Pridopidine Arm of the HEALEY ALS Platform Trial

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, NMJ, Rett, Therapy, Safety, Fast Track, Talisman, Food, Brain-derived neurotrophic factor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Edaravone, Founder, Atrophy, Company, Patient, Hospital, Amyotrophic lateral sclerosis, Axonal transport, Massachusetts General Hospital, Motor neuron, Twitter, Neurodegeneration, Hope, CEO, FDA, Master of Science, Lists of diseases, Mass, Motor neuron disease, ALS, Muscle weakness, BDNF, GDNF, Pharmaceutical industry, HD, MD, Pridopidine, Prilenia, PRIDOPIDINE, PRILENIA

Completing enrollment for the fourth regimen in the Platform Trial brings us closer to discovering new treatments for people living with ALS.

Key Points: 
  • Completing enrollment for the fourth regimen in the Platform Trial brings us closer to discovering new treatments for people living with ALS.
  • In addition to the HEALEY ALS Platform Trial, pridopidine is currently being assessed in PROOF-HD, a global phase 3 clinical trial for Huntingtons Disease (HD).
  • The trial completed patient enrollment ahead of schedule and with numbers over the enrollment target in late 2021.
  • Both trials, the global phase 3 clinical trial in HD (PROOF-HD) and the HEALEY Platform Trial in ALS are currently active and have completed enrollment.

Ketamine Retreat Center, Floresta, Announces New Year's Retreat for December 30th - January 2nd at YO1 Health Resort in the Catskill Mountains, NY

Retrieved on: 
Wednesday, December 1, 2021
Anxiety, Amazon, Mental health, Brain, PTSD, Psychiatry, Yoga, BDNF, ANN, Psychiatric-mental health nurse practitioner, Shannon, Depression, Trauma, Board, OCD, Shamanism, Meditation, Medicine, Pharmaceutical industry

Ketamine is a legal, safe, well-known medication that is currently being prescribed off-label for depression, anxiety, PTSD, trauma, OCD, addiction and other mental health concerns.

Key Points: 
  • Ketamine is a legal, safe, well-known medication that is currently being prescribed off-label for depression, anxiety, PTSD, trauma, OCD, addiction and other mental health concerns.
  • It assists in rewiring the neural network in the brain through an increase in glutamate receptors and brain derived neurotrophic factor (BDNF).
  • This has been shown to have rapid antidepressant and anti-anxiety effects as well as being an effective treatment for many other mental health conditions.
  • She applies her background in meditation, shamanism, indigenous medicine, functional medicine, yoga, and energy work to create game changing possibilities in mental health.

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

Retrieved on: 
Tuesday, November 16, 2021
Quality of life, Cognition, Safety, Compliance, View, Industry, Plasma, News, Clinical trial, DMT, U.S. Securities and Exchange Commission, BDNF, NASDAQ, Maastricht University, MMQ, SEDAR, Emotion, Risk, Creativity, Goal, Multimedia, Research, Software, Medicine, Thought, Pathology, Company, History, EDGAR, Nature, NEO Exchange, DE, Memory, Psilocybin, MDMA, Ibogaine, LSD, Life, NEO, Pharmaceutical industry

Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response.

Key Points: 
  • Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response.
  • The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low dose psychedelics.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
  • Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Prilenia Closes Oversubscribed $43 Million in Series B Financing Round

Retrieved on: 
Wednesday, November 3, 2021
Biotechnology, Pharmaceutical, Health, NMJ, Safety, Dementia, Talisman, Death, Diagnosis, Brain-derived neurotrophic factor, Neurodegeneration, Neuron, Rett, Axonal transport, Motor neuron disease, Twitter, Patient, Founder, BDNF, FDA, Lists of diseases, HD2, Edaravone, Potency (pharmacology), Atrophy, Total functional programming, Venture round, Maintenance, Calcium signaling, Company, Amyotrophic lateral sclerosis, Oxidative stress, Medulla oblongata, CEO, Growth, TFC, Therapy, Muscle weakness, Partner (business rank), Motor neuron, GDNF, HD1, ALS, Pharmaceutical industry, Pridopidine, Prilenia, PRIDOPIDINE, PRILENIA

Prilenia Therapeutics B.V. , a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that it has raised $43M in an oversubscribed Series B financing round.

Key Points: 
  • Prilenia Therapeutics B.V. , a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that it has raised $43M in an oversubscribed Series B financing round.
  • The funding round was upsized and led by new investor Sands Capital, alongside Forbion and Morningside.
  • The Series B financing brings the total capital invested in Prilenia Therapeutics since its founding in September 2018 to $133.5M.
  • "Prilenia has made tremendous progress since its founding through outstanding execution on all fronts, said Geert-Jan Mulder, MD, Prilenia Chairman and Managing Partner at Forbion.